TY  - JOUR
AB  - BACKGROUND AND OBJECTIVE: Junctional epidermolysis bullosa (JEB) is a subtype of epidermolysis bullosa caused by mutations in the LAMB3 gene. We treated a patient with JEB using genetically corrected autologous epidermal cultures retrovirally transduced with the functional LAMB3 gene sequence. The objective of this study was to analyze the skin microbiome of this patient, with a particular focus on transgenic skin, and to compare the findings to the skin microbiome of healthy controls and patients with atopic dermatitis and well-documented microbial dysbiosis. PATIENTS AND METHODS: Skin microbiome analysis was performed on a JEB patient 72 months after combined gene and stem cell therapy. Skin swabs from age-matched healthy controls and atopic dermatitis patients were included from the ProRaD study of CK-CARE. RESULTS: The transgenic skin had comparably high relative and absolute Staphylococcus (S.) aureus abundance to blistering and non-blistering skin of the JEB patient, while the total bacterial load was lower. In blistering skin of the JEB patient, higher bacterial load was driven by S. aureus. CONCLUSIONS: Our investigation confirms a unique microbiome composition in JEB, characterized by S. aureus driven bacterial overgrowth. The dysbiosis was not reversed in transgenic, non-blistering skin areas. However, the transgenic skin demonstrates stability in an environment of bacterial dysbiosis.
AU  - Dermietzel, A.*
AU  - Tosun, B.*
AU  - Nguyen, M.*
AU  - Wessel, K.*
AU  - Rauer, L.
AU  - Neumann, A.U.
AU  - Hirsch, T.*
AU  - Traidl-Hoffmann, C.*
AU  - Reiger, M.*
AU  - Hülpüsch, C.*
AU  - Kueckelhaus, M.*
C1  - 74920
C2  - 57719
TI  - Skin microbiome analysis of a junctional epidermolysis bullosa patient treated with genetically modified stem cells.
JO  - J. Dtsch. Dermatol. Ges.
PY  - 2025
SN  - 1610-0379
ER  - 

TY  - JOUR
AB  - Non-invasive imaging techniques allow a quick and easy in vivo examination of the skin with different penetration depths and resolution depending on the applied technology. Established methods such as dermoscopy and high-resolution sonography of the skin have been an integral part of everyday life for decades. Additionally, new emerging techniques such as optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and line-field confocal OCT (LC-OCT) have entered clinical practice. Multiphoton tomography and optoacoustic imaging are also considered promising new methods. RCM and LC-OCT can also be used ex vivo on freshly excised tissue, for example in Moh's surgery margin assessment. The data generated by all imaging methods is ideal for the application of AI-based algorithms to increase diagnostic accuracy and support experienced users. All mentioned methods have preferred indications depending on their strengths and limitations, both in skin tumor diagnostics and in inflammatory, infectious and parasitic dermatoses. The following guideline provides an overview of the various devices and techniques, explains how each method works and provides the current study situation with indications and limitations of each procedure.
AU  - Deußing, M.*
AU  - Schuh, S.*
AU  - Thamm, J.*
AU  - Winkler, D.*
AU  - Schneider, S.*
AU  - Nau, T.*
AU  - Darsow, U.*
AU  - Schnabel, V.*
AU  - Ulrich, M.*
AU  - Nguyen, L.A.*
AU  - Frenzel, D.*
AU  - Fischer, C.*
AU  - Ruini, C.*
AU  - Ntziachristos, V.
AU  - Kaatz, M.*
AU  - Kurzen, H.*
AU  - Kardorff, B.*
AU  - Herbst, R.*
AU  - Grunewald, S.*
AU  - Sattler, E.*
AU  - Welzel, J.*
AU  - Hartmann, D.*
C1  - 76057
C2  - 58355
TI  - S1 guideline for imaging diagnostics for skin diseases.
JO  - J. Dtsch. Dermatol. Ges.
PY  - 2025
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Heyer, S.*
AU  - Seiringer, P.
AU  - Eyerich, S.
AU  - Pilz, A.C.
AU  - Steimle-Grauer, S.A.*
AU  - Eyerich, K.
AU  - Biedermann, T.*
AU  - Böhner, A.*
C1  - 66172
C2  - 53105
SP  - 1362-1364
TI  - Erfolgreiche Therapie einer akuten generalisierten pustulösen Psoriasis mit dem IL-23p19-Antikörper Risankizumab.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 20
IS  - 10
PY  - 2022
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Seiringer, P.
AU  - Lammer, J.*
AU  - Steimle-Grauer, A.*
AU  - Möckel, S.*
AU  - Zink, A.*
AU  - Biedermann, T.*
C1  - 65723
C2  - 52466
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 1239-1242
TI  - Therapierefraktäre erythematöse Schwellung des Ohres.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 20
IS  - 9
PB  - Wiley
PY  - 2022
SN  - 1610-0379
ER  - 

TY  - JOUR
AB  - Acute or chronic redness of the lower leg is a frequent reason for visits to clinics and practices. The differential diagnosis is often challenging. The aim of this guideline is to define criteria and procedures for the differential diagnosis of acute or chronic, unilateral or bilateral redness of the lower leg. Finding the correct diagnosis is essential for selecting an appropriate treatment and can help to reduce the inappropriate use of antibiotics. The guideline committee identified the most relevant differential diagnoses: 1. erysipelas, 2. stasis dermatitis, 3. hyperergic ictus reaction, 4. superficial and deep vein thrombosis, 5. gout, 6. chronic allergic contact dermatitis, and 7. acute toxic or allergic contact dermatitis. Algorithms/diagnostic pathways, each of which can be broken down into anamnesis, clinical examination, and diagnostics, have been developed for these seven diagnoses. In addition, the guideline group identified over 40 other relevant diagnoses and summarized their characteristics in a table to facilitate further differential diagnoses.
AU  - Zidane, M.*
AU  - Jungkunz, H.W.*
AU  - Kahle, B.*
AU  - Miller, A.*
AU  - Ochsendorf, F.*
AU  - Sunderkötter, C.*
AU  - Traidl-Hoffmann, C.
AU  - Wurpts, G.*
AU  - Nast, A.*
C1  - 67223
C2  - 53520
SP  - 1041-1047
TI  - S1 guideline: Differential diagnosis of acute and chronic redness of the lower legs.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 20
IS  - 7
PY  - 2022
SN  - 1610-0379
ER  - 

TY  - JOUR
AB  - Zusammenfassung Die durch das Coronavirus SARS-CoV-2 verursachte Krankheit COVID-19 hat sich zu einer Pandemie entwickelt. Bei der Betrachtung von dermatologischen und allergologischen Krankheiten, die potenziell von COVID-19 betroffen sind, stehen wir vor komplexen Herausforderungen, die Pathogenese und Beeinflussung verschiedener immunologischer Signalwege einschlie ss en. Medizinische Behandlungen mussen daher im Zusammenhang mit dieser Infektion oft neu bewertet und in Frage gestellt werden. Dieser ubersichtsartikel fasst den aktuellen Wissensstand zu COVID-19 hinsichtlich der wichtigsten dermatologischen und allergologischen Erkrankungen zusammen. Es werden aber auch die medizinischen Bereiche beschrieben, fur die keine ausreichenden Daten vorliegen. Unter Zusammenfassung der publizierten Daten und grundsatzlicher pathophysiologischer uberlegungen werden hier Schlussfolgerungen fur das Management unserer Patienten wahrend der Pandemie gezogen. Wir konzentrieren uns auf haufige Hauterkrankungen mit komplexer immunologischer Pathogenese: Psoriasis, Ekzeme einschlie ss lich atopischer Dermatitis, Typ-I-Allergien, blasenbildende Autoimmundermatosen, Kollagenosen, Vaskulitiden und Hautkrebserkrankung. Da viele weitere Hauterkrankungen verwandte oder vergleichbare immunologische Reaktionsmuster aufweisen, konnen pathophysiologisch ahnliche entzundliche Dermatosen moglicherweise auch mit ahnlichen therapeutischen uberlegungen und Schlussfolgerungen wahrend der Pandemie behandelt werden. Daher soll diese ubersicht Behandlungsempfehlungen auf der Basis bisher publizierter Daten und Empfehlungen zu Therapieentscheidungen auch uber die hier diskutierten, haufigsten Erkrankungen hinaus liefern.
AU  - Buhl, T.*
AU  - Beissert, S.*
AU  - Gaffal, E.*
AU  - Goebeler, M.*
AU  - Hertl, M.*
AU  - Mauch, C.*
AU  - Reich, K.*
AU  - Schmidt, E.*
AU  - Schön, M.P.*
AU  - Sticherling, M.*
AU  - Sunderkötter, C.*
AU  - Traidl-Hoffmann, C.
AU  - Werfel, T.*
AU  - Wilsman-Theis, D.*
AU  - Worm, M.*
C1  - 59957
C2  - 49145
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 815-825
TI  - COVID-19 und Auswirkungen auf dermatologische und allergologische Erkrankungen.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
IS  - 8
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Haufe, E.*
AU  - Heinrich, L.*
AU  - Weisshaar, E.*
AU  - Abraham, S.*
AU  - Heratizadeh, A.*
AU  - Harder, I.*
AU  - Kleinheinz, A.*
AU  - Wollenberg, A.*
AU  - Wiemers, F.*
AU  - Augustin, M.*
AU  - Zink, A.
AU  - von Kiedrowski, R.*
AU  - Fell, I.*
AU  - Pawlak, M.*
AU  - Hilgers, M.*
AU  - Worm, M.*
AU  - Schaekel, K.*
AU  - Sticherling, M.*
AU  - Effendy, I.*
AU  - Staubach-Renz, P.*
AU  - Handrick, C.*
AU  - Bell, M.*
AU  - Asmussen, A.*
AU  - Schwarz, B.*
AU  - Werfel, T.*
AU  - Weidinger, S.*
AU  - Schmitt, J.*
C1  - 58516
C2  - 48133
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 40-41
TI  - Itching and neurodermatitis: Results from the German Neurodermatitis Register TREATgermany.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Rongisch, R.*
AU  - Schmidt, E.*
AU  - Deresz, N.*
AU  - Deresz, K.*
AU  - Schöfer, H.*
AU  - Schäkel, K.*
AU  - Jakob, T.*
AU  - Maurer, M.*
AU  - Sticherling, M.*
AU  - Sunderkötter, C.*
AU  - Babilas, P.*
AU  - Spornraft-Ragaller, P.*
AU  - Traidl-Hoffmann, C.
AU  - Gläser, R.*
AU  - Hartmann, K.*
AU  - Kolb-Mäurer, A.*
AU  - Wenzel, J.*
AU  - Biedermann, T.*
AU  - Homey, B.*
AU  - Pfützner, W.*
AU  - Weid, F.*
AU  - Fischer, M.*
AU  - Linder, R.*
AU  - von Stebut, E.*
C1  - 59075
C2  - 48560
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Travel-associated infectious skin diseases.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
IS  - 7
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AB  - The COVID-19 pandemic caused by SARS-CoV-2 has far-reaching direct and indirect medical consequences. These include both the course and treatment of diseases. It is becoming increasingly clear that infections with SARS-CoV-2 can cause considerable immunological alterations, which particularly also affect pathogenetically and/or therapeutically relevant factors. Against this background we summarize here the current state of knowledge on the interaction of SARS-CoV-2/COVID-19 with mediators of the acute phase of inflammation (TNF, IL-1, IL-6), type 1 and type 17 immune responses (IL-12, IL-23, IL-17, IL-36), type 2 immune reactions (IL-4, IL-13, IL-5, IL-31, IgE), B-cell immunity, checkpoint regulators (PD-1, PD-L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, calcineurin). In addition, we discuss in this context non-specific immune modulation by glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, mycophenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte-mediated innate immune mechanisms. From these recent findings we derive possible implications for the therapeutic modulation of said immunological mechanisms in connection with SARS-CoV-2/COVID-19. Although, of course, the greatest care should be taken with patients with immunologically mediated diseases or immunomodulating therapies, it appears that many treatments can also be carried out during the COVID-19 pandemic; some even appear to alleviate COVID-19.
AU  - Schoen, M.P.*
AU  - Berking, C.*
AU  - Biedermann, T.*
AU  - Buhl, T.*
AU  - Erpenbeck, L.*
AU  - Eyerich, K.*
AU  - Eyerich, S.
AU  - Ghoreschi, K.*
AU  - Goebeler, M.*
AU  - Ludwig, R.J.*
AU  - Schaekel, K.*
AU  - Schilling, B.*
AU  - Schlapbach, C.*
AU  - Stary, G.*
AU  - von Stebut, E.*
AU  - Steinbrink, K.*
C1  - 59897
C2  - 49106
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 795-807
TI  - COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
IS  - 8
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Schoenmann, C.
AU  - Aguirre Bueno, J.
AU  - He, H.
AU  - Berezhnoi, A.
AU  - Hindelang, B.*
AU  - Biedermann, T.*
AU  - Darsow, U.*
C1  - 58514
C2  - 48134
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 27-27
TI  - Optoacoustic imaging in patients with livedoid vasculopathy - Case report.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AB  - Multiple chemical sensitivity (MCS) is a condition characterized by a subjectively perceived increase in sensitivity to environmental chemicals. Individuals affected report a wide variety of nonspecific complaints, and frequently attribute cutaneous and mucosal symptoms to chemical exposures. Dermatologists should therefore be familiar with this condition. MCS is a diagnosis of exclusion. Other causes for the patients' symptoms should be ruled out by routine laboratory tests, allergy tests and, if indicated, monitoring for toxic (environmental) substances. The primary job of dermatologists is to rule out skin diseases or hypersensitivities as possible causes of the complaints. Interdisciplinary patient management is essential, especially in severe cases in which those affected have problems coping with everyday life. Relevant specialties in this context include environmental medicine, psychosomatic medicine as well as occupational and social medicine. Cutaneous symptoms are usually addressed with symptomatic treatment using basic skin care products. There are currently no evidence-based treatment recommendations for MCS. It is crucial that MCS patients be protected from unnecessary treatments and thus from mental, social and financial strain. In addition to medical skills, managing MCS patients requires communicative and psychosocial competence in particular. Physicians involved in the treatment will benefit from training in psychotherapy. Irrespective of the mechanisms that lead to MCS, diagnosis and treatment of this condition require an actively supportive attitude towards these patients, a good doctor-patient relationship and interdisciplinary cooperation.
AU  - Zeiser, K.
AU  - Hammel, G.
AU  - Fleming, M.
AU  - Traidl-Hoffmann, C.
C1  - 58178
C2  - 48161
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 119-131
TI  - Multiple chemical sensitivity (MCS) - a guide for dermatologists on how to manage affected individuals.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 18
IS  - 2
PB  - Wiley
PY  - 2020
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Hindelang, B.*
AU  - Aguirre, J.
AU  - Berezhnoi, A.
AU  - Eyerich, K.*
AU  - Ntziachristos, V.
AU  - Biedermann, T.*
AU  - Darsow, U.*
C1  - 56073
C2  - 46780
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 85-85
TI  - Examination of epicutaneous test reactions using raster-scanning optoacoustic mesoscopy.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 17
PB  - Wiley
PY  - 2019
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Weins, A.B.*
AU  - Mourantchanian, V.*
AU  - Eyerich, S.
AU  - Biedermann, T.*
AU  - Brockow, K.*
C1  - 54483
C2  - 45624
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 1253-1255
TI  - Delayed bullous pressure urticaria: The puzzling role of eosinophils.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 16
IS  - 10
PB  - Wiley
PY  - 2018
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Traidl-Hoffmann, C.
C1  - 49499
C2  - 31624
CY  - Hoboken
SP  - 867-869
TI  - Phytotherapie in der Dermatologie - natürlich gut?!
JO  - J. Dtsch. Dermatol. Ges.
VL  - 14
IS  - 9
PB  - Wiley-blackwell
PY  - 2016
SN  - 1610-0379
ER  - 

TY  - JOUR
AU  - Roenneberg, S.*
AU  - Garzorz-Stark, N.
AU  - Brockow, K.
AU  - Eyerich, K.
AU  - Biederman, T.*
C1  - 46903
C2  - 39018
SP  - 67
TI  - Transplantation of a fixed drug reaction - insights into the resident immune system of the skin.
JO  - J. Dtsch. Dermatol. Ges.
VL  - 13
PY  - 2015
SN  - 1610-0379
ER  -